Anaerobic bacterium as a drug for cancer gene therapy

Details Anaerobic bacterium as a drug for cancer gene therapy Anaerobic bacterium as a drug for cancer gene therapy

2004-02-23

2010-06-22

Long, Scott (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C435S252300, C435S455000

Reexamination Certificate

active

07740835

ABSTRACT:
The present invention provides a bacterium belonging to the genusBifidobacterium, by which DNA coding for a protein having an antitumor activity or DNA coding for a protein having the activity of converting a precursor of an antitumor substance into the antitumor substance is delivered to tumor tissues specifically under anaerobic conditions thereby expressing the protein encoded by the DNA, as well as a pharmaceutical composition comprising said anaerobic bacterium.

REFERENCES:
patent: 4486407 (1984-12-01), Taguchi
patent: 6080849 (2000-06-01), Bermudes et al.
patent: 6190657 (2001-02-01), Pawelek et al.
patent: 6416754 (2002-07-01), Brown et al.
patent: 6447784 (2002-09-01), Bermudes et al.
patent: 6475482 (2002-11-01), Escobedo et al.
patent: 6518062 (2003-02-01), Blanche et al.
patent: 6685935 (2004-02-01), Pawelek et al.
patent: 6863894 (2005-03-01), Bermudes et al.
patent: 6923972 (2005-08-01), Bermudes et al.
patent: 6962696 (2005-11-01), Bermudes et al.
patent: 7354592 (2008-04-01), Bermudes et al.
patent: 2002/0006432 (2002-01-01), Collins et al.
patent: 2002/0182229 (2002-12-01), Brown et al.
patent: 2003/0103952 (2003-06-01), Brown et al.
patent: 2004/0219169 (2004-11-01), Bermudes et al.
patent: 2004/0229338 (2004-11-01), King et al.
patent: 2005/0249706 (2005-11-01), Bermudes et al.
patent: 2007/0009489 (2007-01-01), Bermudes et al.
patent: 98111517 (1998-09-01), None
patent: WO 96/11277 (1995-10-01), None
Yazawa et al. Proceedings of the American Association for Cancer Research Annual Meeting, vol. 40, pp. 88, 1999.
Yazawa et al. (Breast Cancer Research and Treatment, vol. 66, pp. 165-170, 2001).
Natori et al. vol. 70, Issue 12, Dec. 1988, pp. 1765-1774.
Goshima et al. (Biochimie, 1990. vol. 72: 207-214).
Claret et al. (J. Mol. Biol. 1997; 273: 93-104).
M J Lemmon et al., “Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment”, Gene Therapy, vol. 4, 1997, pp. 791-796.
N. Minton et al., “Chemotherapeutic tumor targeting using clostridial spores”, FEMS Microbiology Reviews, vol. 17, 1995, pp. 357-364.
Proceedings, Fifty-Ninth Annual Meeting of the Japanese Cancer Association, Oct. 4-6, 2000, Yokohama, Vo. 91 Supplement, No. 1880 as well as its English translation and Verification of translation.
Yazawa et al., Cancer Gene Therapy, vol. 17, pp. 269-274 published on Mar. 27, 2000 as well as a copy of the certificate.
K. Low et al., “Lipid a mutantSalmonellawith suppressed virulence and TNFα induction retain tumor—targeting in vivo”, Nature Biotechnology, vol. 17, Jan. 1999, pp. 37-41.
G. Dachs et al., “Targeting gene expression to hypoxic tumor cells”, Nature Medicine, vol. 3, No. 5, May 1997, pp. 515-520.
H. Matsumura et al., “Construction ofEscherichia coli-Bifidobacterium longumshuttle vector transforming B.longum105-A and 108-A”, Biosci. Biotech. Biochem., vol. 61, No. 7, 1997, pp. 1211-1212.
A. Argnani et al., “A convenient and reproducible method to genetically transform bacteria of thegenus Bifidobacterium”, Microbiology, vol. 142, 1996, pp. 109-114.
N. Kimura et al., “Selective localization and growth ofBifidobacterium bifidumin mouse tumors following intravenous administration”, Cancer Research, vol. 40, Jun. 1980, pp. 2061-2068.
M. Fox et al., “Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia”, Gene Therapy, vol. 3, 1996, pp. 173-178.
C. Tacket et al., “Comparison of the Safety and Immunogenicity of ΔaroC ΔaroD and Δcya ΔcrpSamonellatyphi Strains in Adult Volunteers”, Infection and Immunity, vol. 60, No. 2, pp. 536-541, Feb. 1992.1.
H. Yasui et al., “Enhancement of Immune Response in Peyer's Patch Cells Cultured withBifidobacterium breve”, Journal of Dairy Science, vol. 74, pp. 1187-1195, 1991.
D. Salzman et al., “AttenuatedSalmonella typhimuriumContaining Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent”, Cancer Biotherapy and Radiopharmaceuticals, vol. 11, No. 2, pp. 145-153, 1996.
J. Saavedra et al., “Feeding ofBifidobacterium bifidumandStreptococcus thermophilusto Infants in Hospital for Prevention of Diarrhoea and Shedding of Rotavirus”, The Lancet, vol. 344, pp. 1046-1049, Oct. 15, 1994.
B. Reddy et al., “Inhibitory Effect ofBifidobacterium longumon Colon, Mannary, and Liver Carcinogenesis Induced by 2-Amino-3-methylirnidazo[4,5-ƒ]quinoline, a Food Mutagen”, Cancer Research, vol. 53, pp. 3914-3918, Sep. 1, 1993.
D. Hone et al., “Evaluation in Volunteers of a Canadidate Live Oral AttenuatedSalmonella typhiVector Vaccine”, Journal of Clinical Investigation, vol. 90, pp. 412-420, 1992.
M. Babincova et al., Life and medical Sciences Online, (2000), 1, pp. 1-4.
IM Verma et al., Nature, “Gene therapy-promises, problems and prospects,” Sep. 1997, vol. 389, pp. 239-242.
WF Anderson, Nature, “Human gene therapy”, Apr. 1998, vol. 392, pp. 25-30.
K Yazawa et al., Breast Cancer Research and Treatment, “Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors,” 2001, 66, pp. 156-170.
Els Kievit et al.: “Superiority of Yeast over Bacterial Cytosine Deaminase for Enzyme/Prodrug Gene Therapy in Colon Cancer Xenografts,” (Cancer Research 59 1417-1421, Apr. 1, 1999).
Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ, Xu GX Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. Feb. 2003;10(2):105-11.
Yi C, Huang Y, Guo ZY, Wang SR. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol Sin. May 2005;26(5):629-34.
Butel et al. “Clostridial pathogenicity in experimental necrotising enterocolitis in gnotobiotic quails and protective role of bifidobacteria” J Med Microbiol 47: 391-399, 1998.
Meer et al. “Human disease associated with Clostrodium perfringens enterotoxin.” Rev Environ Contam Toxicol 150: 75-94, 1997.
Klinger et al. “Clostridium difficile infection: risk factors, medical and surgical management.” Dig Dis 18: 147-160, 2000.
Elmer et al. “Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections.” JAMA 275: 870-876, 1996.
Drlica et al. Histonelike proteins of bacteria. Microbiol Rev 51: 301-319, 1987.
Goshima et al. Characterization of HU-like protein from Bifidobacterium longum. Biochimie 72, 207-212, 1990.
Sayre et al. Construction and properties of a temperature-sensitive mutation in the gene for the bacteriophage SPOI DNA-binding protein TF1. J Bacteriol 172: 4672-4681,1990.
U.S. Appl. No. 11/718,680, filed Jun. 25, 2007, Kano et al.
U.S. Appl. No. 11/910,880, filed Oct. 5, 2007, Hamaji et al.
King. et al.. “Tumor-targeted Salmonella expressing cytosine deaminase converted 5-fluorocytosine to 5-fluoruracil and inhibited tumor growth in vivo,” Abstract from 89thAnnual Meeting of American Association for Cancer Research. 1998.
Pawelek, et al., “Tumor targeted Salmonella as a novel anticancer vector,” Cancer Res. 57:4537-4544, 1997.
Sznol, et al., “Use of preferentially replicating bacteria for the treatment of cancer,” J. Clin. Invest. 105:1027-1030, 2000.
Kohno, et al., “Promoters and autogenous control of theE. colihupA and hupB genes,” J. Mol. Biol. 213:27-36, 1990.
Kohno, et al., “Autoregulation of transcription of the hupA gene inE. coli, evidence for steric hindrance of the functional promoter domains induced by HU,” J. Biochem. 115:1113-1118, 1994.
Tanaka et al., “Properties of DNA-Binding of HU Heterotypic and Homotypic Dimers fromEscherichia coli,” 1993, J. Bi

Affiliated with

Also associated with

Rating

Anaerobic bacterium as a drug for cancer gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anaerobic bacterium as a drug for cancer gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anaerobic bacterium as a drug for cancer gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4202493